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Zika virus, an arthropodborne flavivirus pathogen in hu-
mans, is unusual because it can be sexually transmitted 
and can be shed for prolonged periods in semen. We report 
viral shedding in vaginal secretions for up to 6 months, indi-
cating the potential for sexual and vertical transmission by 
infected women.
Zika virus swept through the Americas beginning in 2014, with >1 million cases reported through Decem-
ber 2017 (Pan American Health Organization, https://www.
paho.org/hq/index.php?option=com_docman&task=doc_
view&Itemid=270&gid=43297&lang=en). Zika virus had 
been considered relatively benign, but during the Americas 
epidemic, several new pathogenic features were identi-
fied: association with severe birth defects in infants born to 
women infected during pregnancy, transmission by sexual 
contact, prolonged shedding in semen, and Guillain-Barré 
syndrome (1–3). Shedding in the female genitourinary tract 
has not been widely reported and remains a serious ques-
tion because of the potential for sexual transmission or as-
cending fetal infection in a pregnant woman (4).
The Study
During October 2016–November 2017, we recruited women 
>18 years of age with symptomatic Zika virus infection (any 
combination of rash, fever, and conjunctivitis for <7 days) 
at a public health center and Hospital Escuela Oscar Danilo 
Rosales Argüello in León, Nicaragua. We enrolled 5 women 
in a prospective cohort to characterize duration of viral shed-
ding in the genital tract. We collected blood by venipunc-
ture, and each woman provided urine and saliva samples.
We tested whole blood, urine, and saliva from each 
woman for Zika virus RNA at enrollment with quantitative 
reverse transcription PCR (qRT-PCR). If we detected Zika 
virus RNA in any fluid, we asked women to provide blood, 
urine, saliva, and vaginal secretions at 7, 14, 21, 28, 60, 
90, and 180 days postonset (dpo) of initial symptoms. We 
collected vaginal fluid using the BBL Culture Swab Col-
lection and Transport System (Becton Dickinson, http://
www.bd.com). Vaginal swabs were self-collected by the 
woman, who inserted the swab ≈5 cm into the vagina, left 
it in place for 5 minutes, removed it, and placed it into swab 
transport media. Women did not provide samples during 
menstruation to avoid contamination with blood. Study 
staff transported the swab specimens at 4°C within 3 hours 
to the Universidad Nacional Autónoma de Nicaragua-León 
microbiology laboratory, where it was stored at 4°C for up 
to 4 months until RNA extraction.
To elute Zika virus RNA, we incubated vaginal swabs 
in 140 µL of phosphate-buffered saline at room temperature 
for 10 min. We extracted Zika virus RNA from the eluent 
using the QIAamp Viral RNA Mini Kit (QIAGEN, https://
www.qiagen.com) according to manufacturer instructions. 
We detected Zika virus RNA by qPCR (AgPath-ID, Ap-
plied Biosystems, https://www.thermofisher.com) on an 
ABI 7500 RT-PCR system (Applied Biosystems) using 
published primers that detect all known Zika virus geno-
types (Zika1087/1108FAM/1163c) and those that are spe-
cific to the Asian genotype (Zika4481/4507cFAM/4552c) 
(5,6). We added 8 µL RNA to 12 µL 2X RT-PCR buffer, 1 
µL (10 pmol) each forward and reverse primers, 1 µL (10 
pmol) probe, 1 µL 25X RT-PCR enzyme mix, and 1.7 µL 
detection enhancer to a final volume of 25 µL. We ampli-
fied Zika virus RNA at 50°C for 30 min and 95°C for 15 
min, followed by 44 cycles of 95°C for 15 s and 60°C for 
1 min. We used QIAGEN AVE buffer as negative RNA 
purification control and DEPC water as no-template con-
trol. The positive control was cell culture supernatant of 
the FP/2013 strain. We defined a positive sample as a cycle 
threshold (Ct) <38 in either reaction.
The study was approved by the institutional review 
boards of Universidad Nacional Autónoma de Nicaragua-
León (acta no. 86, 2016) and University of North Carolina 
at Chapel Hill (protocol no. 16–0541). All subjects provid-
ed written informed consent at enrollment.
Five women with acute Zika virus infection provided 
>1 sample of vaginal secretions. The median age of these 
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participants was 25 years (range 18–54 years). Four wom-
en were pregnant; gestational age at enrollment was 1–8 
months. Infants of all 4 women were healthy at birth with 
no obvious congenital anomalies. The 54-year-old subject 
had hypertension; no other participants reported chronic 
medical conditions. Symptoms started a median of 4 days 
before enrollment (range 1–6 days).
No woman provided samples at all time points because 
of menstruation or lack of follow-up. Of 18 vaginal fluid 
specimens examined, 10 (56%) were Zika virus positive by 
qRT-PCR with >1 of the primer sets, and 3 were positive 
by both. Neither sample collected at 7 dpo was qRT-PCR 
positive, but 2/3 (67%) were Zika virus positive at 14 dpo, 
3/4 (75%) at 21 dpo, 1/3 (33%) at 28 dpo, 2/2 (100%) at 60 
dpo, 1/2 (50%) at 90 dpo, and 1/2 (50%) at 180 dpo. Three 
women had only 1 vaginal fluid sample positive for Zika 
virus by qRT-PCR; 1 had 2 of 3 positive; and 1 woman, 
who shed through 180 dpo, had Zika virus in 5 of 6 samples 
tested (Table).
Conclusions
Detection of Zika virus RNA in vaginal secretions 60–
180 days after the onset of symptoms is a novel obser-
vation; the presence of Zika virus in vaginal secretions 
for <6 months has crucial implications for couples plan-
ning pregnancy and for sexual transmission. In contrast to 
our results, in a population-based study of patients with 
symptomatic acute Zika virus infection followed for 6 
months, only 1 of 50 women had Zika virus detectable in 
vaginal secretions, in a single specimen collected 3 dpo 
(4). The longest previously reported persistence of Zika 
virus RNA in vaginal secretions was 37 dpo (7); no other 
studies have detected Zika virus RNA in the reproductive 
tract for >14 dpo (8). Shedding was intermittent in sev-
eral patients in our study, so 1 negative specimen does not 
necessarily signify viral clearance.
Most of our subjects were pregnant at enrollment; 
pregnant women are known to shed Zika virus in blood for 
up to 3 times longer than nonpregnant women, possibly be-
cause of fetal infection (9). Another study reported detec-
tion of Zika virus RNA in cervical cytology samples of 32 
of 59 pregnant women compared with 18 of 109 nonpreg-
nant women (10). Fetal tissue may act as a reservoir for 
long-term infection, or pregnancy-related immunosuppres-
sion might delay viral clearance. One patient in our study 
(A018) shed Zika virus RNA in the reproductive tract after 
delivery, suggesting that there may be reservoirs of viral 
replication in the female reproductive tract. 
Our findings have implications for future pregnan-
cies. Persistent Zika virus shedding in the reproductive 
tract could be a source of fetal infection. Vaginal shedding 
of Zika virus could result in ascending infection, as oc-
curs with vaginal cervical herpesvirus 2 infections (11), or 
transmission during delivery, as seen with other viral infec-
tions such as human immunodeficiency virus and hepatitis 
B. Alternatively, transplacental infection may occur during 
viremia occurring after sexual transmission. Although the 
role of vaginal replication of Zika virus in fetal infection 
is not well characterized, mouse models suggest that fetal 
infection from vaginal sources of Zika virus replication can 
occur (12,13).
Our findings also suggest that sexual transmission of 
Zika virus from women to their sexual partners may be pos-
sible for up to 6 months after infection. Infectivity stud-
ies are warranted to investigate whether Zika virus shed in 
vagina secretions is capable of replication and infection. 
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Table. Clinical characteristics and viral shedding in 5 women with acute Zika virus infection, Nicaragua, 2016–2017* 
Characteristic A013 A018 A020 A024 A039 
Age, y 54 18 25 19 25 
Duration of symptoms at enrollment, d 1 3 4 6 5 
Pregnant at enrollment No Yes Yes Yes Yes 
Estimated gestational age at enrollment, mo NA 7 7 5 1 
Timing of delivery, days after symptom onset NA 39 61 149 305 
Hematocrit, %, reference range 36–45 36 32 35 37 40 
Leukocytes, cells/mm3, reference range 5,000–10,000 4,230 5,410 3,510 17,430 8,050 
Sexual contact in the last 3 mo† No Yes Yes Yes Yes 
Previous infection with dengue virus† Yes No No No No 
Previous infection with chikungunya virus† Yes Yes No No Yes 
Fluid Zika-positive by qRT-PCR at baseline Saliva Blood, urine Blood Urine Blood, saliva 
Vaginal fluid PCR results, Ct1/Ct2,‡ at approximate days after symptom onset    
 7 NS NS NS 0/0 0/0 
 14 NS 31/0 32/33 NS 0/0 
 21 NS 35/0 34/36 0/0 37/0 
 28 33/0 0/0 NS 0/0 NS 
 60 NS 34/36 NS 36/0 NS 
 90 NS 35/0 NS 0/0 NS 
 180 NS 37/0 0/0 NS NS 
*Ct, cycle threshold; NA, not applicable; NS, no sample; qRT-PCR, quantitative reverse transcription PCR. 
†By participant report. 




Sexually acquired Zika virus, mainly by male-to-female 
transmission, has been reported in >18 articles; however, 
there is evidence of infectious Zika virus particles in vagi-
nal fluids (14). We lacked sufficient sample volumes to per-
form viral culture to distinguish between vaginal shedding 
of viral RNA and replication-competent virions, a limita-
tion of our study. Only 1 report has documented the pres-
ence of culture-confirmed live Zika virus in vaginal secre-
tions from an HIV-infected woman 3 dpo (14), and there is 
1 reported case of likely female-to-male sexual transmis-
sion (15). Larger studies are needed to clarify the potential 
of the female reproductive tract to transmit Zika virus.
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